RETRACTED ARTICLE: High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience

Said, Ebada; Abdulaziz, Badawy A.; Kassas, Mohamed El; Attar, Ibrahim Hussein El; Emadeldeen, Mohammed

doi:10.1007/s00705-020-04639-x

Cited by 12 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results was quite similar to those of a recently published Egyptian study of Said et al 2020 who used the same regimen and recorded 96% of SVR12 [36] Similar studies, but without the same drug regimen, were conducted. In 2015, Lawitz et al carried out a ribavirin-free regimen (SOF, DAC, and SIM) for 12 weeks in 40 treatmentnaive or treatment-experienced patients with decompensated cirrhosis or portal hypertension.…”

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure

Abo-Amer

Badawi

El-Abgeegy³

et al. 2020

Advances in Virology

Self Cite

View full text Add to dashboard Cite

Background and Aims. Direct-acting antivirals (DAAs) have made a revolution in hepatitis C virus (HCV) treatment with promising reduction of HCV infection and disease morbidities. However, unfortunately, treatment failure still occurs in about 5–15% of patients treated with DAA‐based combination regimens. The primary aim of the study was to assess the efficacy and safety of a quadruple regimen of (sofosbuvir, daclatasvir, and simeprevir with a weight-based ribavirin) in chronic HCV DAAs-experienced patients. Methods. This observational, open-label prospective study was carried out on 103 genotype 4 hepatitis C virus-infected patients who failed to achieve SVR12 after sofosbuvir-daclatasvir with or without ribavirin. Patients were treated for three months with sofosbuvir (400 mg), daclatasvir (60 mg), and simeprevir (150 mg) with a weight-based ribavirin dosage (1000–1200 mg/d). Response to treatment was determined by quantitative PCR for HCV at 3 months after the end of treatment (SVR12), and adverse events during the treatment were recorded. Results. SVR was achieved in 100 patients (97.1%) at week 12 after treatment. No dangerous or life-threatening adverse events were recorded. Conclusions. Retreatment of HCV genotype 4 patients with quadruple therapy is a good therapeutic option and achieves high response rates with minimal side effects.

show abstract

Section: Discussionsupporting

confidence: 91%

“…Our results was quite similar to those of a recently published Egyptian study of Said et al 2020 who used the same regimen and recorded 96% of SVR12 [ 36 ]…”

Section: Discussionsupporting

confidence: 91%

Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure

Abo-Amer

Badawi

El-Abgeegy³

et al. 2020

Advances in Virology

Self Cite

View full text Add to dashboard Cite

show abstract

“…These changes were justified by the fact that treatment with sofosbuvir/ daclatasvir; with or without ribavirin, is a low-cost treatment that requires little time to tolerate, has a high success rate in SVR, has few side effects, and has shown high efficacy and safety in treating the chronic HCV patients (Kamal, 2007). According to Said et al, (2020), these medications specifically targeted the viral proteins that are crucial in the process of viral replication. In addition to daclatasvir (DCV), NCCVH has approved sofosbuvir as a potent and pan-genotypic inhibitor of HCV NS5B polymerase.…”

Section: Discussionmentioning

confidence: 99%

Association of multiple mutations in NS5A and NS5B genes and resistance to direct-acting antivirals in chronically infected Egyptian patients with Hepatitis C virus Genotype 4a

M. Mohamed,

B. Barakat,

M. Gado

et al. 2024

Novel Research in Microbiology Journal

View full text Add to dashboard Cite

Approximately 71 million people worldwide are supposed to have chronic hepatitis C virus (CHCV). New direct-acting antiviral (DAA) medications have been used, which helped successfully in complete treatment of CHCV and achieved a sustained virological response (SVR). However, some patients may acquire HCV resistance to DAAs, which may result in treatments failure. The aim of the present study was to compare among the patients that were experiencing virologic relapse (VR) and SVR in relation to the patterns of NS5A and NS5B genes resistance associated substitutions (RASs) in the chronic HCV infected Egyptian patients, who received Sofosbuvir (SOF) and Daclatasvir (DCV) combination therapy. All patients that were infected by chronic HCV had completed treatment with SOF and DCV combination therapy and were followed up after the end of this treatment. A total of 10 out of 100 serum specimens were collected from the enrolled patients and analyzed, where two and eight specimens were representatives for VR and SVR, respectively. These samples had undergone reverse transcriptase-polymerase chain reaction amplification (RT-PCR) of NS5A and NS5B genes, partially sequenced by the Sanger method, and then analyzed phylogenetically to determine their genetic subtypes and RASs. Finally, SVR was gained in all but two patients who were experiencing VR that carried natural NS5A-RASs at positions L31M and Y93H. They were considered as significant for DCV resistance as well as natural NS5B-RASs (T282S), which represented the main polymorphism for SOF resistance. In this study, a number of mutational combinations in the analyzed NS5A and NS5B genes were identified, which may increase the risk of treatments failure in the patients administered regimens including multiple DAA, compared to the baseline sequences of those patients that were experiencing SVR.

show abstract

“…1% [136]. In another study, patients who failed SOF/DCV were retreated successfully with other DAAs [137]. In a recently published study quadruple regimen of (sofosbuvir, daclatasvir, and simeprevir with a weight-based ribavirin) in chronic HCV-G4 DAAs-experienced patients was successful in eradicating the virus [138].…”

Section: Daa Treatment Failuresmentioning

confidence: 99%

Liver Transplantation and HCV Genotype 4

Alghamdi¹,

Al–Hamoudi²

2021

Advances in Hepatology

View full text Add to dashboard Cite

End-stage liver disease secondary to hepatitis C virus (HCV) infection is a major indication for liver transplantation (LT) worldwide. Previous studies have shown a negative impact of HCV on patient and graft survival leading to an inferior transplant outcome when compared to other liver transplant indications. The percentage of HCV patients infected with genotype 4 (G4) among recipients of OLT varies depending on geographic location. In the Middle East HCV-G4 infection is the most common genotype among transplant recipients. Direct antiviral agents (DAAs) have revolutionized the management of HCV infection in the pre- and post-transplant setting. Recent clinical trials have shown high sustained virologic response rates, shorter durations of treatment, and decreased adverse events when compared with the previous treatment of pegylated interferon (PEG-IFN)-based therapy. However, most of these studies were performed in HCV-G1-infected patients. Due to the low prevalence of HCV-G4 in Europe and the USA, this genotype has not been adequately studied in prospective trials evaluating treatment outcomes. The aim of this chapter is to summarize the natural history and treatment outcome of HCV-G4 in the liver transplant setting, with particular attention to new HCV therapies.

show abstract

RETRACTED ARTICLE: High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience

Cited by 12 publications

References 21 publications

Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure

Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure

Association of multiple mutations in NS5A and NS5B genes and resistance to direct-acting antivirals in chronically infected Egyptian patients with Hepatitis C virus Genotype 4a

Liver Transplantation and HCV Genotype 4

Contact Info

Product

Resources

About